Making breast cancer risk clear for women of all ancestries

MyRisk® with RiskScore® estimates an individual patient’s 5-year and lifetime breast cancer risk based on medical history, family history, and genetic markers. Myriad was the first and only lab to make these answers available and accurate for patients of any ancestry.

Delivers personalized care plans

Guides medical management decisions

Calculates 5-year and lifetime risk of breast cancer risk

Meet MyRisk with RiskScore

Request more information or explore ordering options to bring MyRisk hereditary cancer testing to your practice.

Get started with Myriad Oncology

Request more information about how Myriad’s Oncology solutions can benefit you/your patients.


Don't know your NPI? Click Here

By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.

Hidden Fields











Hidden test fields

“While mammograms are an important first step in breast cancer screening, unfortunately it is not always the best modality for screening for breast cancer, specifically for women with dense breast tissue or at a high risk for breast cancer. [Myriad’s MyRisk with RiskScore test] gives high risk assessment and enables providers to offer a screening modality that may not have been eligible before.”

Tyler Freeman, MD

What is MyRisk with RiskScore?

For patients with family history of certain cancers, hereditary cancer testing is the primary way to determine if they are at an increased risk of developing specific types of cancer.

MyRisk with RiskScore evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk. When combined with family history and other clinical factors, MyRisk with RiskScore provides each patient with a cancer risk assessment individualized to them.

Nearly 1 in 4 patients1 meet criteria for hereditary cancer testing

Who is eligible?

Nearly 1 in 4 patients meet the criteria for hereditary cancer testing. Patients may be eligible if someone in their family has been diagnosed with:

  • Breast cancer at age 50 or younger
  • Ovarian cancer at any age
  • Pancreatic cancer at any age
  • Metastatic prostate cancer at any age
  • Male breast cancer at any age

Give your patients a complete answer

When it comes to assessing breast cancer risk, MyRisk goes a step further by giving patients who receive a negative test result a RiskScore.

RiskScore is a component of the MyRisk test that provides a personalized estimate of a person’s likelihood to develop breast cancer over the next 5 years and their lifetime, guiding patients and providers to make more confident and informed medical decisions for managing breast cancer risk.

Take the next step with MyRisk

Get started by downloading the provider guide to learn more.

Hear from patients whose lives have been transformed

Play patient testimonial video - Lisa Wade 0

“My RiskScore indicated that I had an elevated risk of getting breast cancer in my lifetime. Based on these results, I qualified for a breast MRI, which is a screening in addition to my mammogram. MyRisk genetic testing has saved my life.

Lisa Wade

Play patient testimonial video - Ashley Dedmon 0

“I felt really empowered because I knew that should something develop they were gonna catch it early. After talking to my doctor again, we explored preventative options that would drastically reduce my risk, even below the average women.”

Ashley Dedmon

Why choose MyRisk?

Lowest

BRCA1/2 VUS rates

With MyRisk, leverage the industry’s lowest BRCA1/2 VUS rates for clarity in treatment decisions.2

Double

Amount of mutations detected

Panel testing can detect nearly double the amount of mutations compared to single gene testing.3

53%

MyRisk helps patients qualify

53% of patients tested with MyRisk qualify for a change in their medical management vs. approximately 10% expected if tested with other labs.4

Testing process made easy

Myriad provides easy-to-use resources that can seamlessly integrate genetic testing into your practice.

1. Patient identification

OPTIONS

  • Digital screening with MyGeneHistory
  • Radiology Information Systems
  • Mammography Information Systems

2. Pre-test education
(with board-certified genetic counselor)

INCLUDES

  • Individualized education (on-demand)
  • Follow-up documentation (pre-populated test request form, three-generation pedigree, chart notes)

3. Ordering

OPTIONS

  • Online portal
  • Virtual/paper orders
  • EMR integrations
  • Phlebotomy support
  • Technical/ordering support

4. Affordability

INCLUDES

  • Personalized cost estimates
  • 9/10 patients pay $0 ($54 average)
  • Financial assistance and payment plans available

5. Results

INCLUDES

  • Personalized Tyrer-Cuzick/RiskScore with a 5-year and lifetime risk (when applicable)
  • Online portal or results by mail
  • EMR integration
  • Medical management tool included

6. Post-test discussions
(with board-certified genetic counselor)

INCLUDES

  • Individualized discussion of results (on‑demand or scheduled)
  • Detailed summary of notes

Testing process made easy

Myriad provides easy-to-use resources that can seamlessly integrate genetic testing into your practice.

1. Patient identification

OPTIONS

  • Digital screening with MyGeneHistory
  • Radiology Information Systems
  • Mammography Information Systems

2. Pre-test education
(with board-certified genetic counselor)

INCLUDES

  • Individualized education (on-demand)
  • Follow-up documentation (pre-populated test request form, three-generation pedigree, chart notes)

3. Ordering

OPTIONS

  • Online portal
  • Virtual/paper orders
  • EMR integrations
  • Phlebotomy support
  • Technical/ordering support

4. Affordability

INCLUDES

  • Personalized cost estimates
  • 9/10 patients pay $0 ($54 average)
  • Financial assistance and payment plans available

5. Results

INCLUDES

  • Personalized Tyrer-Cuzick/RiskScore with a 5-year and lifetime risk (when applicable)
  • Online portal or results by mail
  • EMR integration
  • Medical management tool included

6. Post-test discussions
(with board-certified genetic counselor)

INCLUDES

  • Individualized discussion of results (on‑demand or scheduled)
  • Detailed summary of notes

MyRisk hereditary cancer 48 gene panel

Genes Breast Ovarian Colorectal Uterine Skin Pancreatic Gastric Prostate Renal Lung Endocrine Other
BRCA1
BRCA2
MLH1
MSH2
MSH6
PMS2
EPCAM
CTNNA1
APC
MUTYH Monoallelic
MUTYH Biallelic
CDKN2A (p16INK4a)
CDKN2A (p14ARF)
CDK4
TP53
PTEN
STK11
CDH1
PALB2
ATM
CHEK2
CHEK2 Biallelic
RAD51C
RAD51D
BARD1
BRIP1
BMPR1A
SMAD4
VHL
RET
MEN1
BAP1
TSC1
TSC2
FH
FLCN
TERT
MITF
MET
SDHA
SDHB
SDHC
SDHD
POLD1
POLE
GREM1
AXIN2
NTHL1 Monoallelic
NTHL1 Biallelic
MSH3 Monoallelic
MSH3 Biallelic
HOXB13
EGFR

MyRisk testing provides you with clear results you can trust

Most hereditary cancer tests only produce positive or negative results. MyRisk takes this a step further, including the MyRisk Management Tool in every report. This easy-to-use guide breaks down everything you need to know about using these results to inform your patient’s personal care plan today and in the future.

MyRisk with RiskScore Patient case study chart

Precision insights to get ahead of cancer

RiskScore estimates an individual patient’s 5-year and lifetime breast cancer risk based on medical history, family history, and genetic markers. Myriad was the first and only lab to make this precision answer available and accurate for patients of any ancestry.

Our research studies

SCIENTIFIC PUBLICATIONS

Variant Classification Discordance: A real-world experience of genetic test results in a community-based setting – Presented at San Antonio Breast Cancer Symposium (SABCS), December 2022

SCIENTIFIC PUBLICATIONS

Driving Down the Rate of Variants of Uncertain Significance as the Myriad MyRisk® Multigene Panel Grows

SCIENTIFIC PUBLICATIONS

Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women

Take the first step towards more informed, personalized cancer care for your patients.

References:
  1. DeFrancesco et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstetrics & Gynecology 2018 – published online before print October 10, 2018.
  2. Mundt E, et al. Driving Down the Rate of Variants of Uncertain Significance as the Myriad MyRisk® Multigene Panel Grows [White paper]. Myriad Genetics. Oct 2019.
  3. Yorczyk A, et al. Use of panel tests in place of single gene tesets in the cancer genetics clinic. Clin Genet. 2015 Sep;88(3):278-282.
  4. Myriad internal data based on MyRisk tests reported between 9/1/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers.